바이오시밀러 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 적응증별, 제품별, 지역별, 경쟁별 세분화(2020-2030년)

The Global Biosimilars Market will grow from USD 31.07 Billion in 2024 to USD 42.36 Billion by 2030 at a 5.30% CAGR. Biosimilars are biological medical products highly similar to an already approved original biologic, known as the reference product, demonstrating no clinically meaningful differences in safety, purity, and effectiveness. The global biosimilars market's growth is primarily driven by the imminent patent expiry of numerous blockbuster biologics, compelling the demand for more affordable therapeutic alternatives, alongside the increasing prevalence of chronic diseases globally.

Key Market Drivers

The global biosimilars market expansion is fundamentally propelled by the imminent patent expiration of numerous high-value biologic drugs, creating substantial opportunities for more affordable alternatives. The pharmaceutical industry is currently navigating a significant $236 billion patent cliff projected between 2025 and 2030, with nearly 70 blockbuster products set to lose exclusivity and open their therapeutic areas to biosimilar competition. This widespread loss of exclusivity acts as a primary catalyst, enabling biosimilar manufacturers to develop and launch products that directly compete with established biologics.

Key Market Challenges

The inherent manufacturing complexities and high associated costs represent a significant impediment to the global biosimilars market's expansion. Developing and producing biosimilar products requires extensive investment in research, highly specialized manufacturing facilities, and stringent purification processes due to their intricate biological nature. These factors directly contribute to extended development timelines and elevated capital expenditure for biosimilar manufacturers, creating substantial financial outlay and technical hurdles.

Key Market Trends

The global biosimilars market is significantly influenced by the expansion into GLP-1 agonist biosimilars, marking a strategic pivot towards high-demand therapeutic areas. This trend addresses the substantial patient populations grappling with chronic conditions such as type 2 diabetes and obesity, promising to broaden access and alleviate healthcare costs. The entry of biosimilar versions of these highly effective drugs is poised to intensify competition and foster innovation within this lucrative segment.

Key Market Players

• Dr. Reddy's Laboratories Ltd.
• Sandoz Group AG
• Coherus Biosciences
• Viatris Inc.
• Bio-Thera Solutions
• Pfizer Inc.
• Apobiologix
• Teva Pharmaceuticals
• Biocon Ltd
• Reliance Life Sciences

Report Scope:

In this report, the Global Biosimilars Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biosimilars Market, By Indication:

• Oncology
• Inflammatory and autoimmune diseases
• Chronic diseases
• Blood disorders
• Growth hormone deficiency
• Infectious diseases
• Others

Biosimilars Market, By Product:

• Monoclonal antibodies
• Insulin
• Granulocyte colony-stimulating factor
• Erythropoietin
• Recombinant human growth hormone
• Etanercept
• follitropin
• Teriparatide
• Interferons
• Anticoagulants
• Others

Biosimilars Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biosimilars Market.

Available Customizations:

Global Biosimilars Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biosimilars Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Oncology, Inflammatory and autoimmune diseases, Chronic diseases, Blood disorders, Growth hormone deficiency, Infectious diseases, Others)
  • 5.2.2. By Product (Monoclonal antibodies, Insulin, Granulocyte colony-stimulating factor, Erythropoietin, Recombinant human growth hormone, Etanercept, follitropin, Teriparatide, Interferons, Anticoagulants, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Biosimilars Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Product
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Biosimilars Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Product
  • 6.3.2. Canada Biosimilars Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Product
  • 6.3.3. Mexico Biosimilars Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Product

7. Europe Biosimilars Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Product
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Biosimilars Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Product
  • 7.3.2. France Biosimilars Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Product
  • 7.3.3. United Kingdom Biosimilars Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Product
  • 7.3.4. Italy Biosimilars Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Product
  • 7.3.5. Spain Biosimilars Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Product

8. Asia Pacific Biosimilars Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Product
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Biosimilars Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Product
  • 8.3.2. India Biosimilars Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Product
  • 8.3.3. Japan Biosimilars Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Product
  • 8.3.4. South Korea Biosimilars Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Product
  • 8.3.5. Australia Biosimilars Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Product

9. Middle East & Africa Biosimilars Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Product
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Biosimilars Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Product
  • 9.3.2. UAE Biosimilars Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Product
  • 9.3.3. South Africa Biosimilars Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Product

10. South America Biosimilars Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Product
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Biosimilars Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Product
  • 10.3.2. Colombia Biosimilars Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Product
  • 10.3.3. Argentina Biosimilars Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Product

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Biosimilars Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Dr. Reddy's Laboratories Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sandoz Group AG
• 15.3. Coherus Biosciences
• 15.4. Viatris Inc.
• 15.5. Bio-Thera Solutions
• 15.6. Pfizer Inc.
• 15.7. Apobiologix
• 15.8. Teva Pharmaceuticals
• 15.9. Biocon Ltd
• 15.10. Reliance Life Sciences

16. Strategic Recommendations

17. About Us & Disclaimer